Literature DB >> 11062201

Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

H Okamoto1, S Miyazaki, K Tateda, Y Ishii, K Yamaguchi.   

Abstract

The in vitro activities (MIC and MBC) of telithromycin (HMR 3647) against clinical isolates in Japan were investigated in comparison with those of erythromycin A, clarithromycin, azithromycin, amoxycillin, cefdinir and levofloxacin. Telithromycin was more potent than the reference compounds against erythromycin A-susceptible or resistant Streptococcus pneumoniae isolates possessing either mef (mefA or mefE) genes or the ermB gene. Against erythromycin A-susceptible or inducibly resistant Staphylococcus aureus and erythromycin A-susceptible and intermediate Enterococcus faecalis, telithromycin was highly active.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11062201     DOI： 10.1093/jac/46.5.797

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  8 in total

1.  CEM-101 activity against Gram-positive organisms.

Authors:  Leah N Woosley; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

3.  Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA.

Authors:  Mingfu Liu; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  H Okamoto; S Miyazaki; K Tateda; Y Ishii; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 6.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Authors:  Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

Authors:  Charles M Fogarty; Tushar C Patel; Lala M Dunbar; Bruno P Leroy
Journal:  BMC Infect Dis       Date:  2005-05-31       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.